Status:
UNKNOWN
The Application of Indocyanine-Green(ICG) Fluorescence Imaging in Hepatocellular Carcinoma
Lead Sponsor:
Zhujiang Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
This study aims to evaluate the feasibility of indocyanine green (ICG)-based fluorescence imaging in the detection of liver tumors. By correlating the ICG fluorescence patterns with pathologically con...
Eligibility Criteria
Inclusion
- 18 years≤ Age ≤70 years
- Compling with the diagnosis criteria of hepatic carcinoma.
- Primary hepatic carcinoma without intrahepatic or extrahepatic extensive cancer metastasis, the metastatic hepatic carcinoma whose primary focal has been controlled.
- Preoperative liver function is Child - Pugh grade A or B.
- The patients are volunteered for the study.
Exclusion
- Patients with mental illness.
- Patients can't tolerate the operation owe to a variety of basic diseases (such as severe cardiopulmonary insufficiency, renal insufficiency, cachexia and blood system diseases, etc.
- The patients refused to take part in the study.
- There are other co-existed malignant tumors.
- Benign liver diseases.
- Indocyanine green allergy
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03793322
Start Date
January 1 2017
End Date
December 31 2020
Last Update
January 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510282